CDK6 and ovarian carcinoma: Everolimus decreased expression of CDK6 and cyclin D1 and increased expression of p21 in both cell lines after 24 hours of treatment (Figure 2C), suggesting that everolimus induces growth inhibition through induction of G1 phase arrest in ovarian cancer cells.